NDA 022225 · Msd Sub Merck
Bridion
Sugammadex Sodium · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Dec 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Dec 15, 2015
Approved uses
5
Original approval plus efficacy supplements
Registered trials
274
45 Phase 3, 13 recruiting
FAERS reports
2,731
2,306 serious, 104 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 13, 2026.
BRIDION ® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery. BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery. ( 1 )
Mechanism: BRIDION is a modified gamma cyclodextrin. It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2024 Supplement 14 · Efficacy · priority review LetterLabel
- Jun 25, 2021 Supplement 8 · Efficacy LetterLabel
- Jan 22, 2021 Supplement 7 · Efficacy LetterLabel
- Jun 9, 2020 Supplement 6 · Efficacy LetterLabel
- Dec 15, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewSummary Review
2 products under this application
- BRIDION · SUGAMMADEX SODIUM EQ 500MG BASE/5ML (EQ 100MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- BRIDION · SUGAMMADEX SODIUM EQ 200MG BASE/2ML (EQ 100MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Sugammadex" as an intervention, any sponsor and status, largest first.
University of California, Los AngelesAcademic, hospital or other
NCT04263363 · 12,248 participants · Start Feb 18, 2022 · Primary completion May 7, 2024
Drug: Sugammadex 100 MG/ML [Bridion] · For: Respiratory Complication; Obstructive Sleep Apnea
Sites: Los Angeles, California
- Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01422304 · 1,198 participants · Start Oct 12, 2011 · Primary completion Sep 26, 2012
Drug: Sugammadex; neostigmine and glycopyrrolate or atropine and 2 more · For: Neuromuscular Blockade; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee and 2 more
- Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal SurgeryPivotal-lookingNot yet recruiting
Xijing HospitalAcademic, hospital or other
NCT07271875 · 560 participants (planned) · Start Jan 1, 2026 · Primary completion Nov 30, 2027
Drug: Neostigmine + Atropine; Sugammadex · For: Postoperative Gastrointestinal Dysfunction (POGD); Postoperative Ileus; Colorectal Surgery
- Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean SectionPivotal-lookingCompleted
Brno University HospitalAcademic, hospital or other
NCT01718236 · 500 participants · Start Sep 2012 · Primary completion Jan 2015
Drug: Rocuronium + sugammadex; Succinylcholine + Neostigmine · For: Caesarean Section; Pregnancy
Sites: Olomouc, Czechia; Brno, Czechia
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney DiseasePivotal-lookingRecruiting
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT07203287 · 490 participants (planned) · Start Aug 26, 2025 · Primary completion Dec 31, 2026
Drug: Rocuronium; Cisatracurium and 2 more · For: Post Operative Pulmonary Complications; Neuromuscular Blockade; General Anesthesia
Sites: Galveston, Texas
- Sugammadex Hypersensitivity Study (Study P06042)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00988065 · 448 participants · Start Sep 6, 2009 · Primary completion Apr 13, 2010
Drug: Placebo run-in dose; Sugammadex 4 mg/kg and 2 more · For: Hypersensitivity
- Influence of Neostigmine vs. Sugammadex on PORC and PPCs by UltrasonographyPivotal-lookingStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT05040490 · 414 participants (planned) · Start Aug 31, 2021 · Primary completion Jul 2022
Drug: sugammadex as reversal drugs · For: Postoperative Pulmonary Complications
- A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02028065 · 382 participants · Start Jan 3, 2014 · Primary completion Jul 1, 2014
Drug: Sugammadex; Placebo · For: Hypersensitivity; Anaphylaxis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic reaction315
- bradycardia285
- cardiac arrest195
- anaphylactic shock174
- bronchospasm173
- hypotension165
- drug ineffective145
- recurrence of neuromuscular blockade107
- off label use96
- oxygen saturation decreased95
- drug interaction78
- dyspnoea71
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 34 |
| 2013 | 50 |
| 2014 | 35 |
| 2015 | 49 |
| 2016 | 204 |
| 2017 | 226 |
| 2018 | 286 |
| 2019 | 274 |
| 2020 | 225 |
| 2021 | 209 |
| 2022 | 217 |
| 2023 | 255 |
| 2024 | 240 |
| 2025 | 272 |
| 2026 | 150 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database.
Liu H, Yang Q, Li Z, et al. · Int J Surg 2025 · Systematic Review
- Sugammadex vs neostigmine in post-anesthesia recovery: A systematic review and meta-analysis.
Zhu N, Li Y · Biomol Biomed 2025 · Systematic Review, Meta-Analysis
- Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.
Hristovska AM, Duch P, Allingstrup M, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Systematic Review
- The Efficacy and Adverse Effects of Sugammadex and Neostigmine in Reversing Neuromuscular Blockade Inpatients with Obesity Undergoing Metabolic and Bariatric Surgery: A Systematic Review with Meta-Analysis and Trial Sequential Analysis.
Wang S, Dong Y, Wang S, et al. · Medicina (Kaunas) 2024 · Systematic Review, Meta-Analysis
- Sugammadex in Colorectal Surgery: A Systematic Review and Meta-analysis.
Chen AT, Patel A, McKechnie T, et al. · J Surg Res 2022 · Meta-Analysis, Systematic Review
- The effect of sugammadex on postoperative urinary retention and recovery characteristics: a systematic review and meta-analysis.
Ni Z, Sun R, Zhang Q, et al. · BMC Anesthesiol 2025 · Systematic Review, Meta-Analysis
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.